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Alternative splicing in neuropathology <p>A novel microarray technology that permits the screening of alternative splice variants identifies disease-associated alternative splicing  patterns in ion channel genes of patients with mesial temporal lobe epilepsy and Alzheimers disease.</p>
Abstract
Background:  Alternative gene transcript splicing permits a single gene to produce multiple
proteins with varied functions. Bioinformatic investigations have identified numerous splice
variants, but whether these transcripts are translated to functional proteins and the physiological
significance of these alternative proteins are largely unknown. Through direct identification of splice
variants associated with disease states, we can begin to address these questions and to elucidate
their roles in disease predisposition and pathophysiology. This work specifically sought to identify
disease-associated alternative splicing patterns in ion channel genes by comprehensively screening
affected brain tissue collected from patients with mesial temporal lobe epilepsy and Alzheimer's
disease. New technology permitting the screening of alternative splice variants in microarray
format was employed. Real time quantitative PCR was used to verify observed splice variant
patterns.
Results:  This work shows for the first time that two common neurological conditions are
associated with extensive changes in gene splicing, with 25% and 12% of the genes considered
having significant changes in splicing patterns associated with mesial temporal lobe epilepsy and
Alzheimer's disease, respectively. Furthermore, these changes were found to exhibit unique and
consistent patterns within the disease groups.
Conclusion:  This work has identified a set of disease-associated, alternatively spliced gene
products that represent high priorities for detailed functional investigations into how these changes
impact the pathophysiology of mesial temporal lobe epilepsy and Alzheimer's disease.
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Background
The complexity of the genome lies not only in the many genes
comprising it, but also in the many levels of processing that
influence the proteins that are produced and their abun-
dance. One key site of regulation is the splicing of precursor
RNAs to their associated mRNA transcripts. This process
alone allows a single gene to have multiple different mRNA
transcripts, producing proteins that may differ substantially
from one another, even to the extent of having opposing
effects [1]. Overall, however, little is known about the func-
tional differences amongst the alternative proteins produced
from the same gene. Because the functional characterization
of proteins can be laborious, it would be useful to be able to
prioritize alternative transcripts more likely to have biological
significance. One direction for prioritization is on the basis of
association with human disease.
Alternative splicing of key genes generates alternative pro-
teins that contribute to several prominent human diseases,
for example, the spinal motor neuron protein in spinal mus-
cular atrophy [2], cardiac troponin T, insulin receptor, myo-
tubularin-related 1, and other proteins in myotonic
dystrophies [3-5], and the tau protein in frontotemporal
dementia and Alzheimer's disease [3,4] (other examples are
reviewed extensively in [5]). Furthermore, alternative splic-
ing of a sodium channel gene, SCN1A, has also recently been
associated with altered response to antiepileptic medications
[6]. There are potentially many more undetected examples of
splicing alterations associated with disease pathophysiology
and drug response variation in humans.
Studies of alternative splicing have usually been restricted to
a single gene or small gene family. To date, there are only a
few reports of splice variation screens in human disease and
none has been reported for any central nervous system dis-
ease. Recently, new technology has become available that
allows for the comprehensive investigation of alternative
splicing through the use of splice variant microarrays. This
technology uses probes in a microarray format and screens
for unique exon-exon junctions specific to a particular splic-
ing event [7-10]. Here we applied this systematic approach to
assess the relationship between alternative splicing and two
common and important neurological conditions, with the aim
of identifying alternative splicing patterns of potential rele-
vance to human disease.
Mesial temporal lobe epilepsy (mTLE) and Alzheimer's dis-
ease (AD) are highly complex neurological diseases charac-
terized by aberrant neuronal excitation and
neurodegeneration. While the pathological processes differ
substantially, both diseases exhibit pathophysiology linked to
ion channel activity. Seizure activity characteristic of epilepsy
is the result of a dysregulation of inhibitory and excitatory
neuronal signaling largely controlled by ion channel activity
[11]. Likewise, abnormal ion channel function also has been
associated extensively with AD. AD-related neurodegenera-
tion is believed to be, in part, caused by the overactivation of
N-methyl-D-aspartate receptor activation and subsequent
increases in intracellular calcium, oxidative stress, and neu-
rodegeneration [12]. Other ion channels, including glutamate
receptors, nicotinic cholinergic receptors, and calcium and
potassium channels, also have been implicated in AD patho-
physiology [13-18]. Little information exists regarding the
impact of splicing variation of ion channel genes on mTLE
and AD. Our work sought to comprehensively evaluate ion
channel splice variation in these two neurological diseases
using a microarray format (ExonHit Therapeutics). We eval-
uated 1,665 known and potential splice events across 287 ion
channel genes in human brain tissue samples collected from
patients with AD and mTLE. In addition to identifying dis-
ease-associated splicing variation, a secondary aim of this
work was to assess the reliability of the array-based identifi-
cation of splicing changes through the use of real time PCR
(rtPCR) to validate associations detected using the high-
throughput platform.
Results
Mesial temporal lobe epilepsy
Following our initial screen of 1,665 possible alternative splic-
ing events, a total of 221 splicing changes were identified as
statistically significantly changed in mTLE samples, with p <
0.05, when comparing splice variant ratio (SVR) values calcu-
lated using equation 1 (see Materials and methods). Selected
statistically significant events representing a range of p values
were chosen for rtPCR confirmation. Of 13 splice array-iden-
tified alternative splicing events with an associated p value of
less than 0.05, 9 were verified using rtPCR in a larger sample
size. Evaluation of discrete groups of p value ranges revealed
increased success rates with lower p values (0.02 <p < 0.05,
0% success (two events evaluated); 0.01 < p < 0.02, 70% suc-
cess (seven events evaluated); p  < 0.01, 100% success (3
events evaluated)). In order to report changes most likely to
be real, only events that had a p value in splice array analyses
of less than 0.02 are reported (Table 1). With this additional
filter, a total of 126 alternative splicing events were observed
in brain tissue collected from mTLE patients. As additional
confirmation, four events not identified as changed in the
splice array screen (p  > 0.05) were confirmed not to be
changed using rtPCR. The compiled list of rtPCR confirmed
mTLE-associated alternative splicing events are included in
Table 2.
Our splice array studies revealed an mTLE-associated splic-
ing change in CACNA1B  (p  = 0.017, variant GenBank:
M94173). This particular event was randomly selected for
rtPCR confirmation, and we observed a change opposite that
detected with the splice array. This likely occurred due to the
presence of unknown splicing events that were being detected
either by the splice array probes, or possibly by the rtPCR
assay probes. Due to the uncertainty linked to this event, we
deemed this splicing change in our studies as an event thathttp://genomebiology.com/2007/8/3/R32 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. R32.3
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Table 1
List of ion channel genes exhibiting alternative splicing in patients with mTLE
Genes by gene class GenBank accession 
number 
(reference transcript*)
GenBank accession 
number 
(variant transcript*)
Alternative splicing event: change of 
mRNA transcript composition in 
epilepsy†
Alternatively 
spliced region
Splice array 
p value
Calcium channels
CACNA1A NM_023035 U79668 ES: 26% ↓ variant/reference ratio EXON 48 0.002
NM_023035 CQ723237 ASA: 24% ↓ reference/total ratio EXON 23 0.003
NM_023035 BE972738 NE: 36% ↓ variant/total ratio 3' downstream <0.001
CACNA1C NM_000719 CQ722696 ASD: 94% ↓ variant/reference ratio EXON 2 <0.001
NM_000719 CQ722691 ASD: 23% ↓ variant/reference ratio EXON 24 0.017
CACNA1H NM_021098 CQ730788 ASA: 25% ↓ variant/reference ratio EXON 34 <0.001
CACNA1I NM_001003406 AX068892 NE: 36% ↓ variant/reference ratio INTRON 1 0.012
NM_001003406 AX068892 NE: 23% ↓ variant/reference ratio INTRONS 20/21 0.009
CACNA2D1 NM_000722 BG211441 ES: 28% ↑ reference/total ratio EXON 8 0.003
CACNB1 NM_000723 NM_199247 NE: 28% ↑ variant/reference ratio INTRON 6 <0.001
NM_000723 BP316738 NE: 28% ↑ variant/reference ratio INTRON 6 0.002
CACNB2 NM_201596 AF465485 ES: 20% ↓ variant/reference ratio EXON 7 0.020
CACNB3 NM_000725 AK122911 NEs: 28% ↓ variant/total ratio 5' upstream <0.001
CACNB4 NM_000726 AY054985 NE: 31% ↑ variant/reference ratio INTRON 2 0.012
CACNG4 NM_014405 AW134993 PIED: 45% ↑ reference/total ratio EXON 4 0.009
NM_014405 AI675178 PIED: 41% ↓ variant/reference ratio EXON 4 0.003
Chloride channels
CLCN2 NM_004366 BC021578 ES: 38% ↓ reference/total ratio EXON 13 <0.001
CLCN3 NM_001829 CQ732096 ASA: 22% ↓ variant/reference ratio EXON 2 0.004
NM_001829 CQ736554 NE: 32% ↑ reference/total ratio INTRON 12 0.012
CLCN6 NM_001286 BC050457 ASA: 16% ↓ variant/reference ratio EXON 20 0.016
CLCN7 NM_001287 AK096963 IR: 36% ↓ variant/reference ratio INTRON 18 <0.001
NM_001287 BQ920088 ASA: 21% ↓ variant/reference ratio EXON 12 0.004
CLIC5 NM_016929 BC039380 ASA: 20% ↓ reference/total ratio EXON 5 0.013
Sodium channels
SCN2A2 NM_021007 BC029489 ES: 23% ↑ reference/total ratio EXON 1 0.006
SCN9A NM_002977 BG108767 ASD: 26% ↓ variant/reference ratio EXON 16 0.003
SCNN1A NM_001038 BF033087 PIED: 21% ↓ variant/reference ratio EXON 13 <0.001
SCNN1D NM_002978 AX230571 NE: 52% ↑ variant/total ratio INTRON 2 0.012
NM_002978 AK127357 NE: 77% ↑ variant/total ratio 5' upstream 0.002
Potassium channels
KCNAB2 NM_003636 BG720519 ES: 35% ↑ variant/reference ratio EXON 1 0.014
NM_003636 BM823724 NEs: 19% ↓ variant/total ratio 5' upstream 0.015
NM_003636 CA495339 IR: 24% ↓ reference/total ratio INTRON 11 0.020
KCNC3 NM_004977 AK127492 ASD: 27% ↓ variant/reference ratio EXON 5 0.020
KCNH5 NM_172376 NM_139318 NE: 24% ↑ variant/total ratio 3' downstream <0.001
KCNJ1 NM_153767 NM_000220 NE: 27% ↓ variant/reference ratio INTRON 3 <0.001
KCNJ6 NM_002240 CQ738104 NEs: 24% ↓ variant/total ratio INTRON 2 0.017
KCNJ15 NM_170736 NM_002243 NE: 108% ↑ variant/total ratio 5' upstream <0.001
NM_170736 NM_170737 NE: 2.5x ↑ reference/total ratio INTRON 2 <0.001
NM_170736 CQ732921 NEs: 42% ↓ variant/reference ratio INTRON 2 0.005
NM_170736 BM544058 NE: 98% ↑ variant/total ratio 5' upstream <0.001
NM_170736 BF105170 NE: 78% ↑ variant/total ratio 5' upstream 0.003
NM_170736 BI518753 NE: 2.5x ↑ reference/total ratio INTRON 2 <0.001
KCNK1 NM_002245 AV733795 PIED: 34% ↓ variant/reference ratio EXON 2 0.010
NM_002245 BG699040 NE: 45% ↓ variant/total ratio INTRON 1 0.009
NM_002245 BF212472 NEs: 23% ↓ variant/total ratio INTRON 1 0.017
NM_002245 BU661246 NEs: 48% ↓ variant/total ratio INTRON 1 <0.001
KCNK2 NM_014217 BU956092 ES: 62% ↑ reference/total ratio EXON 4 0.008
KCNK4 NM_016611 NM_033310 NE: 102% ↑ variant/total ratio 5' upstream 0.005R32.4 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. http://genomebiology.com/2007/8/3/R32
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KCNK12 NM_022055 AX302031 NEs: 20% ↓ variant/total ratio INTRON 1 0.014
KCNMA1 NM_002247 CQ870200 NE: 24% ↓ variant/reference ratio EXON 20 0.006
NM_002247 CQ870204 PIED: 32% ↓ variant/reference ratio 3' downstream 0.020
NM_002247 BG185868 NE: 28% ↓ variant/reference ratio EXON 9 0.014
KCNN2 NM_021614 NM_170775 NE: 26% ↓ variant/total ratio INTRON 3 0.002
KCNQ2 NM_004518 AY358189 NE: 28% ↓ variant/reference ratio INTRON 7 0.018
NM_004518 BG772772 NEs: 23% ↓ variant/reference ratio INTRON 7 0.018
HCN3 NM_020897 CQ715247 EsS: 15% ↓ variant/reference ratio EXONS 3-4 0.012
SLICK NM_198503 CQ728754 EsS: 28% ↓ reference/total ratio EXONS 22-25 0.019
NM_198503 CQ728754 ES: 57% ↑ variant/reference ratio EXON 15 0.003
GABA receptors
GABRA2 NM_000807 CD014113 ES: 26% ↑ reference/total ratio EXON 8 <0.001
NM_000807 CD014116 EsS: 29% ↑ reference/total ratio EXONS 4-9 <0.001
NM_000807 CD014112 EsS: 35% ↑ reference/total ratio EXON 4 <0.001
NM_000807 CD014107 EsS: 31% ↑ reference/total ratio EXONS 7/8 <0.001
NM_000807 CD014110 EsS: 36% ↑ reference/total ratio EXONS 6-8 <0.001
NM_000807 CD014109 EsS: 40% ↑ reference/total ratio EXONS 6/7 <0.001
GABRA3 NM_000808 AX897950 ES: 17% ↓ reference/total ratio EXON 7 0.007
GABRG2 NM_198904 NM_198903 ASA: 22% ↑ reference/total ratio EXON 4 0.005
GABRR1 NM_002042 CB959800 NEs: 17% ↓ variant/total ratio 5' upstream 0.007
Ionotropic glutamate receptors
GRIA1 NM_000827 A46050 NE: 34% ↓ variant/reference ratio INTRON 14 0.012
NM_000827 M64752 NE: 39% ↓ variant/reference ratio INTRON 14 0.008
GRIA2 NM_000826 BC010574 NE: 44% ↓ variant/reference ratio INTRON 13 0.007
NM_000826 AX147452 NE: 61% ↓ variant/reference ratio INTRON 13/
EXON14
0.005
NM_000826 AV748963 NE: 44% ↓ variant/reference ratio EXON 14 0.015
GRIA3 NM_007325 NM_181894 NEs: 19% ↑ variant/reference ratio INTRON 2 0.006
GRIK2 NM_021956 CQ715784 ASD: 65% ↓ reference/total ratio EXON 10 <0.001
GRIK4 NM_014619 CQ869986 NEs: 29% ↓ variant/total ratio 5' upstream 0.006
NM_014619 CQ715345 NE: 31% ↓ variant/total ratio INTRON 4 0.015
NM_014619 CQ715345 ES: 23% ↑ reference/total EXON 7 0.005
GRIK5 NM_002088 CQ719647 ASD: 24% ↓ reference/total ratio EXON 16 0.008
NM_002088 AX665460 ASD: 23% ↓ variant/reference ratio EXON 18 0.004
NM_002088 CN420154 EsS: 27% ↓ variant/reference EXONS 12-14 0.020
FXYD domain ion transport regulators
FXYD1 NM_021902 BQ181273 IR: 51% ↓ variant/reference ratio INTRON 7 <0.001
FXYD6 NM_022003 AX430335 NE: 31% ↓ variant/total ratio 5' upstream <0.001
NM_022003 AX892598 NE: 35% ↓ variant/total ratio 5' upstream <0.001
NM_022003 BC018652 NEs: 38% ↓ variant/reference ratio EXON 1/INTRON 
1
<0.001
NM_022003 AL832811 NE: 33% ↓ variant/reference ratio INTRON 1 <0.001
NM_022003 AW270073 ES: 34% ↓ variant/reference ratio EXON 9 <0.001
NM_022003 BI823239 NE: 48% ↓ variant/reference ratio INTRON 1 <0.001
NM_022003 BF527041 NE: 36% ↓ variant/reference ratio INTRON 1 0.002
NM_022003 BP372334 NE: 45% ↓ variant/reference ratio INTRON 1 <0.001
NM_022003 BE263758 NE: 37% ↓ variant/reference ratio EXON 2 <0.001
NM_022003 BX488702 ASA: 50% ↓ variant/reference ratio INTRON 2 <0.001
NM_022003 BI598749 NE: 40% ↓ variant/reference ratio INTRON 1 0.006
FXYD7 NM_022006 CQ722304 ES: 21% ↓ variant/reference ratio EXON 4 0.007
Transient receptor potential cation 
channels
TRPA1 NM_007332 BF570694 ASD: 37% ↓ reference/total ratio EXON 25 <0.001
Table 1 (Continued)
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TRPC4 NM_016179 AF421362 ES: 24% ↓ reference/total ratio EXON 3 0.004
TRPM1 NM_002420 AX480882 ASD:43% ↓ variant/reference ratio EXON 17 <0.001
TRPM7 NM_017672 CQ728707 EsS: 35% ↑ variant/reference ratio EXONS 7-11 <0.001
TRPV1 NM_080704 NM_080705 NE: 31% ↑ variant/total ratio INTRON 1 0.007
NM_080704 AX686983 ES: 35% ↑ variant/reference ratio EXON 8 0.005
TRPV2 NM_016113 BQ645005 ASD: 25% ↓ variant/reference ratio EXON 15 0.005
Glycine receptors
GLRB NM_000824 CD013911 ES: 31% ↑ variant/reference ratio EXON 9 0.004
Inositol triphosphate receptors
ITPR1 NM_002223 CQ727353 EsS: 22% ↑ variant/reference ratio EXONS 52-54 0.020
Purinergic receptors
P2RX1 NM_002558 BM469621 NE: 57% ↑ variant/total ratio INTRON 3 <0.001
NM_002558 BP372168 ASD: 17% ↑ reference/total ratio EXON 1 0.002
P2RXL1 NM_005446 BC064805 ASD: 24% ↑ variant/reference ratio EXON 1 0.013
Cyclic nucleotide gated channels
CNGA1 NM_000087 CN366905 NEs: 20% ↓ variant/total ratio 5' upstream 0.011
CNGB3 NM_019098 AI150392 ES: 19% ↓ variant/total ratio EXON 18 0.016
Amiloride-sensitive cation channel
ACCN2 NM_020039 BC028722 NE: 19% ↓ variant/reference INTRON 3 0.017
NM_020039 AX683970 NE: 23% ↓ variant/reference INTRON 3 0.019
Two pore segment channels
TPCN1 NM_017901 CQ729206 ASA: 27% ↑ variant/reference ratio EXON 10 <0.001
TPCN2 NM_139075 AW178475 NE: 87% ↑ variant/total ratio INTRON 9 <0.001
Mucolipin
MCOLN1 NM_020533 BQ723075 ASD: 17% ↓ variant/reference ratio EXON 2 <0.001
NM_020533 CA489568 ASD: 69% ↑ variant/reference ratio EXON 7 0.011
Ryanodine receptors
RYR3 NM_001036 CQ730808 ES: 28% ↑ variant/total ratio EXON 84 0.017
Miscellaneous other ion channels/
interacting proteins
C6orf69 NM_173562 BC023525 EsS: 33% ↑ reference/total ratio EXONS 3-5 0.003
KCNIP2 (potassium channel interacting 
protein)
NM_014591 NM_173191 ASA: 37% ↑ variant/reference ratio EXON 3 0.004
NM_014591 NM_173193 EsS: 19% ↑ variant/reference ratio EXONS 2-3 0.018
NM_014591 NM_173197 ES: 9% ↓ reference/total ratio EXON 7 0.015
MLC1 (megalencephalic leuko-
encephalopathy with subcortical cysts)
NM_015166 BX451200 ASD: 31% ↓ variant/reference ratio EXON 8 0.009
PKD1L2 (polycystic kidney disease 1-like) NM_052892 CQ741519 ES: 82% ↑ variant/reference ratio EXON 7 0.006
PKD2L2 (polycystic kidney disease 2like) NM_014386 AF182034 NEs: 38% ↑ variant/total ratio INTRON 13/3' 
downstream
0.005
SH3KBP1 (SH3KBP1 binding protein) NM_138392 BX366064 ASD: 26% ↓ variant/reference ratio EXON 10 0.002
NM_138392 AL523485 ASD: 26% ↑ reference/total ratio EXON 13 0.005
VGCNL1 (voltage-gated channel) NM_052867 BM556576 NE: 31% ↓ variant/total ratio INTRON 7 <0.001
NM_052867 AK094669 EsS: 28% ↓ reference/total ratio INTRON 12 0.019
*Reference transcript refers to traditionally spliced gene product, while the variant refers to the alternatively spliced mRNA transcript. †Change was quantified using splice 
array samples (control versus mTLE temporal cortex, n = 10/group). The ratio selected to quantify an event was determined based on best available probe choice (see 
Materials and methods section). ASA, alternative splice acceptor site; ASD, alternative splice donor site; ES, exon skipped; EsS, exons skipped; IR, intron retention; NE, novel 
exon; NEs, novel exons; PIED, partial internal exon deletion.
Table 1 (Continued)
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rtPCR failed to confirm and, therefore, it is not included in
Table 1. Given our results in our rtPCR confirmation analyses
of array-detected events, we believe this occurs relatively
infrequently, but this does bring to light a shortcoming of the
splice array technology in accurately detecting complex series
of alternative splicing events that occur in a gene region.
Nearly 25% of all genes represented on the splice variant
microarray were alternatively spliced in mTLE compared to
control. Following normalization of the number of genes
found to be alternatively spliced to the total number of genes
in the gene class, calcium channels, chloride channels, and
glutamate receptors were found to exhibit the most mTLE-
associated alternative splicing events, with nearly 30% of
genes in these classes found to be alternatively spliced in this
disease state.
A representative mTLE-associated alternative splicing event
is shown in Figure 1. This selected event in the CLCN7 gene
results in the inclusion of an intronic sequence located
between exons 17 and 18 (Figure 1a). Both the splice array
data and the rtPCR confirmation revealed a net reduction in
the variant form containing the intronic sequence in mTLE
brain tissue samples (Figure 1b). Furthermore, with reverse
transcriptase amplification of the transcript variants in
selected brain tissue samples, we show both the presence of
the two transcript forms and the effects of the disease state on
reducing the variant splice form of CLCN7 (Figure 1c).
Alzheimer's disease
For AD, 1,479 potential splicing events passed the criteria on
probe quality for the control 2 versus AD comparison. Using
the SVR ratios shown in equation 2 (see Materials and meth-
ods), we found that 43 events reached a nominal significance
level of 0.05 for comparison between cases and controls
(Table 3). Five out of six randomly selected events that exhib-
ited a p value less than 0.05 also were found to be significantly
changed when subjected to more quantitative rtPCR analysis
in a larger sample size (Table 2). Additionally, four events not
identified as statistically significantly changed in the splice
array screen (p > 0.05) were confirmed not to be changed
using rtPCR.
The splice array screen revealed 12% of ion channel genes in
these experiments to be alternatively spliced in AD, with
greater than 20% of genes comprising the calcium channel,
chloride channel, sodium channel, and glutamate receptor
gene class exhibiting AD-associated alternative transcript
splicing. When compared to mTLE, there are fewer alterna-
tive splicing events in AD. Several explanations could account
for this, with the simplest being that there are more alterna-
tive splicing events in mTLE compared to AD. On the other
hand, the larger number of alternative splicing events in
mTLE also could be explained by tissue differences between
freshly resected and postmortem tissue. However, if this were
the case and transcript degradation in the time prior to brain
tissue collection were contributing to some of the observed
splicing changes, we would expect to see a correlation
Table 2
List of alternative splicing events confirmed using rtPCR
Gene GenBank accession number 
(reference transcript*)
GenBank accession number 
(variant transcript*)
Alternative splicing event: change of mRNA 
transcript composition in disease state†
Alternatively 
spliced region
rtPCR p value
mTLE
CACNB1 NM_000723 NM_199247 NE: 65% ↑ variant/reference ratio INTRON 6 0.035
CACNB4 NM_000726 AY054985 NE: 4.2x ↑ variant/reference ratio INTRON 2 0.027
CLCN7 NM_001287 AK096963 IR: 65% ↓ variant/total ratio INTRON 18 <0.001
FXYD6 NM_022003 BP372334 NE: 22% ↓ variant/reference ratio INTRON 1 <0.001
GRIA1 NM_000827 A46050 NE: 62% ↓ variant/reference ratio INTRON 14 0.002
KCNK1 NM_002245 AV733795 PIED: 13% ↓ variant/total ratio EXON 2 <0.001
KCNQ2 NM_004518 AY358189 NE: 34% ↓ variant/total ratio INTRON 7 <0.001
MCOLN1 NM_020533 CA489568 ASD: 47% ↑ variant/reference ratio EXON 7 <0.001
AD
CACNA1G NM_018896 NM_198376 PIED: 67% ↓ variant/total ratio EXON 36 <0.001
GABRA6 NM_000811 AK090735 IR: 30% ↓ variant/reference ratio INTRON 6 0.007
GRIA1 NM_000827 A46050 NE: 2.5x ↑ variant/reference ratio INTRON 14 0.001
KCNAB1 NM_172160 NM_172159 NE: 75% ↓ variant/reference ratio INTRON 1 0.004
KCNN1 NM_002248 BM718136 ASD: 25% ↓ variant/reference ratio EXON 6 <0.001
KCNN2 NM_021614 BG769522 ES: 85% ↓ variant/reference ratio EXON 3 0.002
MCOLN1 NM_020533 CA489568 ASD: 19% ↑ variant/reference ratio EXON 7 0.016
*Reference transcript refers to traditionally spliced gene product, while the variant refers to the alternatively spliced mRNA transcript. †Splice array 
determined results were confirmed using quantitative rtPCR in a larger sample size (control (n = 28-29) versus mTLE neocortex (n = 43); control (n 
= 27) versus AD (n = 31) temporal cortex and cerebellum). ASA, alternative splice acceptor site; ASD, alternative splice donor site; ES, exon skipped; 
EsS, exons skipped; IR, intron retention; NE, novel exon; NEs, novel exons; PIED, partial internal exon deletion.http://genomebiology.com/2007/8/3/R32 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. R32.7
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between the splice variant proportions and time of brain tis-
sue collection. This was not observed for any of the SVRs for
splicing events identified in this study (data not shown).
Another possible explanation might be that, in the AD cases,
normalization of changes in the temporal cortex to those in
the cerebellum reduces the baseline human-to-human varia-
bility in splicing proportions, thereby reducing the number of
falsely identified events. While theoretically this could be the
reason for the difference in the number of splicing events
identified in mTLE and AD, caution should be used in accept-
ing this interpretation. The comparison between AD and con-
trol is performed after two normalization steps, with the first
being a probe normalization, followed by a brain region nor-
malization. This results in an additional normalization step
compared to the mTLE samples and, while reducing the sub-
ject-to-subject variability, the interassay variability is
increased due to the compounding variability added with
each ratio taken. It is possible that the extra normalization
step results in more missed events due to an increase in vari-
ability. In fact, the GRIA1  (ionotropic (AMPA) glutamate
receptor) gene was identified as a potential splice variant
associated with AD in a preliminary study using the splice
array technology (in n = 4 samples). In rtPCR this event was
confirmed (Table 2) in a larger sample size. However, when
Representative mTLE-associated alternative splicing event identified using splice array technology Figure 1
Representative mTLE-associated alternative splicing event identified using splice array technology. (a) Schematic of CLCN7 alternative splicing event 
associated with mTLE. Exons are shown in orange and intronic regions are shown in gray. (b) Data collected for the CLCN7 alternative splice event in 
control and mTLE brain tissue samples using the splice array technology (left) and quantitative rtPCR (qrtPCR, right). Data are presented as mean ± 
standard error of the mean; *p < 0.05 when compared to control, Student's t-test. (c) rtPCR confirmation of the pattern of transcript expression in brain 
tissue collected from ten subjects from each group. Both reference and variant transcript forms were amplified using the following primer sequences 
(indicated in the figure by arrows above mRNA transcripts): CLCN7F-GGCAAATACGCCCTGATG, CLCN7R-CTCAGCACGTCCACAATGAC.
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Table 3
List of ion channel genes exhibiting alternative splicing in patients with Alzheimer's Disease
Genes by gene class GenBank accession 
number (reference 
transcript*)
GenBank accession 
number (variant 
transcript*)
Alternative splicing 
event: change of 
mRNA transcript 
composition in AD†
Alternatively spliced 
region
Splice array p value
Calcium channels
CACNA1A NM_023035 CQ723237 ASA: 23% ↓ 
reference/total ratio
EXON 23 0.007
NM_023035 U79668 ASD: 36% ↓ variant/
reference ratio
EXON 48 0.022
CACNA1C NM_000719 CQ722691 ASD: 19% ↑ 
reference/total ratio
EXON 27 0.033
CACNA1G NM_018896 NM_198376 PIED: 14% ↓ variant/
reference ratio
EXON 36 <0.001
CACNA1I NM_001003406 AX068892 ASD: 29% ↓ variant/
total ratio
EXON 16 0.049
CACNA2D1 NM_000722 BG210356 NE: 55% ↑ reference/
total ratio
INTRON 3 0.021
Chloride channels
CLCN2 NM_004366 BC021578 ES: 14% ↓ reference/
total ratio
EXON 13 0.041
NM_004366 BF002578 NE: 38% ↓ variant/
total ratio
3' downstream 0.042
CLCN6 NM_001286 NM_021736 ES: 15% ↓ reference/
total ratio
EXON 12 0.022
CLCNKA NM_004070 CQ733615 ASD: 27% ↓ variant/
reference
EXON 15 0.039
Sodium channels
SCN2A2 NM_021007 CQ730725 ES: 16% ↓ variant/total 
ratio
EXON 11 0.023
SCN7A NM_002976 BC062699 ES: 39% ↓ reference/
total ratio
EXON 1 0.027
SCNN1D NM_002978 AX230571 ASA: 17% ↓ variant/
reference ratio
EXON 1 0.045
Potassium channels
KCNAB1 NM_172160 NM_172159 NE: 21% ↓ variant/
reference
INITRON 1 0.028
KCNAB2 NM_003636 AI933060 NE: 51% ↓ variant/
total ratio
3' downstream 0.017
NM_003636 AI090677 NEs: 105% ↑ variant/
reference ratio
INTRON 7 0.039
NM_003636 BM925038 PIED: 65% ↑ variant/
reference ratio
EXON 16 0.045
KCNF1 NM_002236 AI566537 PIED: 51% ↑ variant/
reference ratio
EXON 1 0.045
KCNG1 NM_172318 BF569197 ASD: 23% ↓ variant/
reference ratio
EXON 1 0.005
NM_172318 AI968477 ASD: 28% ↑ 
reference/total ratio
EXON 1 0.031
KCNH5 NM_172376 NM_139318 ES: 14% ↑ reference/
total ratio
EXON 11 0.033
KCNMB2 NM_181361 NM_005832 NEs: 25% ↓ variant/
total ratio
INTRON 1 0.030
KCNN1 NM_002248 BX106650 ASD: 47% ↑ 
reference/total ratio
EXON 6 0.004http://genomebiology.com/2007/8/3/R32 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. R32.9
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NM_002248 BM718136 ASD: 39% ↑ 
reference/total ratio
EXON 6 0.015
KCNQ2 NM_004518 NM_172107 NE: 70% ↑ variant/
reference ratio
INTRON 10 0.038
NM_004518 BG772772 NEs: 55% ↑ variant/
reference ratio
EXONS 7-9 0.016
KCNQ3 NM_004519 CQ725469 PIED: 47% ↓ 
reference/total ratio
EXON 15 0.036
GABA receptors
GABRA3 NM_000808 AX897950 ES: 48% ↑ reference/
total ratio
EXON 7 0.037
GABRA5 NM_000810 AL035782 EsS: 65% ↑ variant/
reference ratio
EXONS 2/3 0.030
GABRA6 NM_000811 AK090735 IR: 72% ↓ variant/total 
ratio
INTRON 6 0.037
Ionotropic 
glutamate receptors
GRIK2 NM_021956 CQ715784 ASD: 57% ↓ 
reference/total ratio
EXON 10 0.007
GRIK4 NM_014619 CQ734018 NEs: 35% ↓ variant/
total ratio
INTRON 1 0.006
GRIK5 NM_002088 AJ249209 NE: 52% ↑ variant/
reference ratio
INTRON 18 0.037
Transient receptor 
potential cation 
channels
TRPM7 NM_017672 CQ728707 ES: 6% ↓ reference/
total ratio
EXON 4 0.048
FXYD domain ion 
transport regulators
FXYD5 NM_014164 BU164524 NE: 36% ↓ variant/
reference ratio
INTRON 1 0.030
Inositol 
triphosphate 
receptors
ITPR1 NM_002222 CQ719499 ES: 15% ↓ reference/
total ratio
EXON 23 0.030
Two pore segment 
channels
TPCN1 NM_017901 BG899733 NE: 49% ↑ variant/
reference ratio
INTRON 1 0.016
Mucolipin
MCOLN1 NM_020533 CA489568 ASD: 95% ↑ variant/
reference ratio
EXON 7 0.026
NM_020533 AJ293659 IR: 33% ↑ variant/total 
ratio
INTRON 5 0.032
Table 3 (Continued)
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additional samples were studied by splice array analysis, this
event was no longer detected as being changed in the com-
plete sample set (n = 10) employed in this arm of the study.
This also occurred for the alternative splicing event of the
KCCN2 gene in AD. This strongly suggests that our list of
events is a minimum estimate of the ion channel splice events
that are associated with AD. However, in order to minimize
the number of false positives we report due to human-to-
human variability (in most cases considered to be greater
than interassay variability), we applied a conservative data
analysis approach given the tissue samples available to us for
these studies.
A representative AD-associated alternative splicing event is
shown in Figure 2. This selected event in the GABRA6 gene
results in the inclusion of an intronic sequence located
between exons 6 and 7 (Figure 2a). Both the splice array data
and the rtPCR confirmation revealed a reduction in the vari-
ant form containing the intronic sequence in AD brain tissue
samples (Figure 2b). In the splice array evaluation of this
event, a statistically significant reduction was observed in
t e m p o r a l  c o r t e x  f r o m  A D  s u b j e c t s  c o m p a r e d  t o  c o n t r o l s ,
while no such change was seen in the cerebellar samples.
Quantitative rtPCR revealed, however, a statistically signifi-
cant AD-associated reduction in the variant form in both the
temporal cortex and cerebellum, with a much larger change
detected in the temporal cortex. Given the enhanced sensitiv-
ity of rtPCR, this difference is not unexpected and likely
results from rtPCR picking up on a more subtle change in the
cerebellum. Reverse transcriptase amplification of the tran-
script variants in selected brain tissue samples reveals the
effects of the disease state on reducing the variant splice form
of GABRA6, with a greater magnitude of change in the tran-
scripts containing the intronic region detected in the disease-
affected brain tissue structure (temporal cortex, Figure 2c).
Discussion
Bioinformatic investigations have permitted the comprehen-
sive compilation of expressed sequence tag (EST) and cDNA
databases that identify potential sites of alternative splicing
in human genes. The technological capability now exists to
discover the extent to which splicing changes are present in
human disease. Using mTLE and AD as prototypical neuro-
logical diseases, we specifically sought to identify alternative
splice variants of ion channel genes in human brain tissue
samples to address the following goals: to compile a list of ion
channel genes in mTLE and AD that undergo alternative
splicing; and to validate the use of new technology in the eval-
uation of ion channel splice variation for a large set of genes
in a high-throughput manner. Based on these results, we pro-
pose a strategy for selection of the most clinically relevant
splicing changes to be pursued in further functional and
mechanistic studies.
Disease-associated alternative ion channel splicing
Alternative splicing of ion channels in mTLE
The splice array technology identified widespread alternative
splicing changes associated with mTLE. Importantly, the
well-characterized mTLE-associated flip-flop alternative
splicing events of the ionotropic glutamate receptor (splicing
change conserved across all neuronally expressed GRIA
genes) were detected in both GRIA1 and GRIA2 genes in these
experiments (Table 1). Our results are in agreement with the
previously published finding of an upregulation of the flip
splice form in mTLE [19,20].
Ryanodine 
receptors
RYR1 NM_000540 CQ717972 PIED: 30% ↑ 
reference/total ratio
EXON 91 0.011
NM_000540 CQ730824 ES: 35% ↑ variant/
reference ratio
EXON 35 0.042
Miscellaneous other 
ion channels/
interacting proteins
TM4SF11 (plasmolipin) NM_015993 R16034 NE: 21% ↑ variant/
reference ratio
INTRON 1 0.016
GMRP-1 (potassium 
channel tetramerization 
protein)
NM_032320 BG722430 NE: 26% ↑ variant/
reference ratio
INTRON 1 0.031
*Reference transcript refers to traditionally splicing gene product, while the variant refers to the alternatively spliced mRNA transcript. †Change was 
quantified using splice array samples (control versus AD temporal cortex, n = 10/group). The ratio selected to quantify event was determined based 
on best available probe choice (see Materials and methods section). ASA, alternative splice acceptor site; ASD, alternative splice donor site; ES, exon 
skipped; EsS, exons skipped; IR, intron retention; NE, novel exon; NEs, novel exons; PIED, partial internal exon deletion.
Table 3 (Continued)
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We also have demonstrated splicing changes in many genes
with known associations to human epilepsies. Specifically, we
have identified two mTLE-associated splicing events (Table 1)
in the KCNQ2 gene, which encodes a voltage-gated potassium
channel. This gene is of particular interest in epilepsy as sev-
eral mutations in it have been associated with benign familial
neonatal convulsions [11,21-26]. Furthermore, many of the
mutations have been located in splice sites surrounding exons
[23,24,26], possibly implicating them in alternative splicing
events identified herein. Several other genes that we have
identified as undergoing mTLE-linked alternative splicing
events also have been associated with other, non-mTLE forms
of human epilepsy, including CACNA1A, CACNA1H, CLCN2,
and GABRG2 [27-30], indicating that these also may be of
particular interest in the epilepsy field.
We emphasize that in screening for alternative splicing events
associated with mTLE, we employed neocortical brain tissue.
While the hippocampus is generally felt to be the disease
focus in this form of epilepsy, the hippocampus is also the site
of greatest tissue damage. The intent of this work was to
investigate a high-throughput method of splice variant iden-
tification. Therefore, to reduce potential confounding issues
of significant non-uniform neuronal loss and/or altered cellu-
lar composition, we pursued changes in the temporal neocor-
tex, adjacent to the diseased hippocampus, rather than in the
hippocampus itself. We believe that this approach minimizes
Representative AD-associated alternative splicing event identified using splice array technology Figure 2
Representative AD-associated alternative splicing event identified using splice array technology. (a) Schematic of GABRA6 alternative splicing event 
associated with mTLE. Exons are shown in orange and intronic regions are shown in gray. (b) Data collected for the GABRA6 alternative splice event in 
control and AD brain tissue (TC and CB) samples using the splice array technology (left) and quantitative rtPCR (qrtPCR, right). Data are presented as 
mean ± standard error of the mean; *p < 0.05 when compared to control, Student's t-test. (c) rtPCR confirmation of the pattern of transcript expression 
in brain tissue collected from ten subjects from each group. Reference and variant transcript forms were amplified using the following primer sequences 
(indicated in the figure by arrows above mRNA transcripts): reference GABRA6F-AAGAATCTTCAAGCCTTCTCCA, GABRA6R-
TGACAGCTGCGAACTCGATA, variant GABRA6F-AAGAATCTTCAAGCCTTCTCCA, GABRA6F-TCCAAGATTACACAAATCTTTATATGC.
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the number of artifactual splicing changes. Now that a list of
potential TLE-linked splicing changes has been identified,
a d d i t i o n a l  w o r k  i s  n e e d e d  t o  evaluate the extent of these
changes in the hippocampus. To do this it will be necessary to
use laser capture microdissection to separate intact neurons
in the hippocampus to assess splice variation in homogene-
ous cell populations in this brain structure. Events that occur
more extensively in the hippocampus compared to the neo-
cortical tissue may indicate a more direc t  r o l e  i n  d i s e a s e
pathology.
Alternative splicing of ion channels in AD
AD also revealed extensive alternative ion channel splicing.
No information has been reported to date regarding alterna-
tive splicing of ion channel genes associated with AD,
although several ion channels that we have identified as
undergoing alternative splicing have been implicated in AD.
Specifically, our data show a splicing change in GRIA1 in AD
(Table 3). GRIA1 encodes an ionotropic (AMPA) glutamate
receptor, one of a class of genes that have been extensively
linked to cognition and memory [31]. A downregulation of
GRIA1  expression has been observed in diseased brain
regions collected from subjects with AD [14,17,18]. Further-
more, mice deficient in GluR-A (encoded by gria1) have been
shown to have deficits in long-term potentiation and reduc-
tions in spatial working memory tasks [32-34]. Therefore,
alternative splicing of the GRIA1 gene may have a pathophys-
iological role in AD. Based on previous literature, the splicing
change identified in ITPR1 (Table 3) may also play an impor-
tant role in AD. Presenilin, a transmembrane protein local-
ized to endoplasmic reticulum, is required for the proteolysis
of amyloid precursor protein. Evidence suggests that muta-
tions in the presenilin gene causing early onset AD [35] may
result in alterations in inositol-triphosphate signaling (via
ITPR  receptors) to increase intracellular calcium [36]. In
addition to alternative splicing in ITPR1, our data also show
several alternative splicing events in calcium channel genes
that also may factor into the pathway of intracellular calcium
dysregulation commonly associated with AD [15].
Validation of disease-associated alternative splicing
The splice array technology has proven valuable for compre-
hensively identifying splice variation across a large set of
genes. The accuracy of the splice array technology is evident
by the reproducibility of the results using more quantitative
rtPCR. While events could have been missed using our data
analysis strategy, the reported list likely reflects few false pos-
itive results given the follow-up rtPCR success rate and the
reproducibility in a relatively large sample size. Collectively
evaluating all of our rtPCR confirmation studies, we estimate
that >80% of all array-identified splicing changes (Tables 1
and 3) are real events.
All splicing events identified in this work exhibit only small
magnitude changes, with the maximum exceeding just over a
2.5-fold change. Despite the relatively low magnitude of
changes, if these transcripts encode proteins with altered
function then the biological consequences could be substan-
tial. The fact that previously identified splicing changes in the
GRIA genes, which have been well-established in the litera-
ture to be involved in both human epilepsy and animal mod-
els [19,20,37-40], were observed in mTLE brain tissue at only
a 30% increase suggests that these low level splicing changes
could be real and biologically important alternative splicing
events.
To provide further validation of the accuracy of the technol-
ogy in identifying true alternative splicing differences in the
experimental groups, we employed principal component and
k-means clustering analyses to collectively evaluate patterns
of splicing changes in the brain tissue samples. Regression
analysis of the first two principal components (PCs; Figure 3)
indicates that the largest sources of variability are accounted
for by brain structures (temporal cortex or cerebellum) and
by disease state. Across PC1 and PC2 combined, 37% of vari-
ation is explained by membership of the epilepsy (mTLE NC)
group. Outside of epilepsy samples, 30% is explained by dif-
ferences in brain tissue type, and an additional 11% is
explained by differences between AD and control samples
(combining main and interaction effects with tissue type). We
note that while the majority of the control temporal cortex
(Control TC) samples cluster together, these samples have
several outliers from the dominant cluster (blue cluster, Fig-
ure 3). This is likely due to the lack of homogeneity of these
patients with regard to disease states, past medical history,
and current medications at the time of death. In fact, with
regard to the medical history of the controls, all that is known
is that they did not have epilepsy and had minimal cognitive
dysfunction. Despite the lack of precise grouping in the con-
trols, the mTLE and AD subjects cluster together well and, in
both conditions, the groups do diverge from the dominant
control subject cluster. Importantly, the clustering analyses
place the control, AD, and mTLE temporal cortex results pre-
dominantly in unique groups, while the control and AD cere-
bellar samples are largely grouped together (Figure 3a).
Given that the cerebellum in AD patients is considered a
largely unaffected brain structure, the overlap of control and
AD cerebellum results is not unexpected and validates the use
of this structure as an internal control for improving the abil-
ity to detect disease related changes in the temporal cortex.
Furthermore, for AD it was possible to distinguish the
contribution of disease state in both the temporal cortex
(affected in AD) and cerebellum (largely unaffected in AD)
using linear regression modeling.
Using this approach, we determined that, in the temporal cor-
tex, 20% of the variability accounted for by PC1 and PC2 is
attributed to disease state, whereas in the cerebellum only
0.4% of the variability could be accounted for by AD-status.
Taken together, these analyses provide strong validation for
the accuracy of the splice array in detecting real alternative
splicing changes in the disease states.http://genomebiology.com/2007/8/3/R32 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. R32.13
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Effects of altered cellular composition in disease states
Both mTLE and AD are diseases that result in neurodegener-
ation in patients to varying degrees between affected individ-
uals and between brain regions. A concern arises that the
alternative splicing changes we are observing in this work are
due to alteration in cellular composition. To address this
issue, we undertook immunoblot analysis to assess neuronal
and glial cell numbers. Immunoblot results were obtained for
control (n = 24), mTLE (n = 22), and AD (n = 31) temporal
cortex. Samples that did not have adequate protein amount to
evaluate their NeuN (neuronal nuclei, neuronal marker) and
GFAP (glial fibrillary acidic protein, glial cell marker)
amounts accurately were excluded from the analysis. Despite
the ability to detect group-specific changes in cellular popula-
tions (Additional data figure 1 in Additional data file 2),
neither the splice array-determined splice proportions, nor
data collected using rtPCR, showed any statistically signifi-
cant correlation to the NeuN or GFAP protein content. A rep-
resentative graph showing this lack of correlation is given in
Additional data figure 2 (in Additional data file 2) for
MCOLN1 SVR in control, mTLE, and AD temporal cortical
tissue. All other events demonstrated a similar lack of corre-
lation between SVRs and NeuN or GFAP protein concentra-
tion. Although immunoblotting might not be quantitative
enough to detect slight changes in cellular composition that
likely are occurring in these brain tissue samples, given that
w e  w e r e  a b l e  t o  d e t e c t  q u a n titative differences between
experimental groups (Additional data figure 1 in Additional
data file 2) consistent with neurodegeneration (Additional
data file 1), we believe that alterations in cellular composition
are not the major cause of the observed disease-associated
splicing changes.
Functional consequences of alternative splicing
Splice variants with known function
We cannot determine if particular splice variant transcripts
identified in this work are translated into proteins with
altered function, if translation does not occur for a splice var-
iant, or if a resulting protein is immediately degraded because
of dysfunctional activity. Theoretically, more drastic changes
could result from a translated protein with altered function,
otherwise alteration would simply be a low level expression
change. Few splicing events detected by the splice array have
information about the presence of an associated protein and
even fewer have functional data available for the proteins
translated from the splice variant transcripts. Of all events
identified in our work, only CACNB4 (GenBank: AY054985;
Tables 1 and 2) and the previously reported GRIA gene splic-
ing changes (flip-flop), identified to be present in increased
quantities in mTLE patients, have data regarding the func-
tional consequences of the splice variant [37,41].
CACNB4 encodes the β subunit of calcium channels and mod-
ulates the activity of the pore-forming α subunits [42]. The
function of the protein produced from the splice variant com-
pared to the normal transcript was studied in Xenopus
oocytes in the presence of α subunits. The protein encoded by
the splice variant inactivated at a faster rate and the voltage
dependence of the α/β complex was shifted to more depolar-
ized potentials in the presence of the splice variant of
CACNB4 [41]. Thus, in the presence of this splice variant, the
neuron may be more likely to depolarize with a smaller stim-
ulus. The GRIA gene splice variants also have been shown to
exhibit electrophysiological properties consistent with
enhanced cellular excitability [37]. While the direct biological
consequences of the CACNB4  and  GRIA  gene splicing
changes in patients with mTLE cannot be concluded from this
work, the observation of expressed proteins with altered func-
tion is important and warrants follow-up investigations to
decipher how the changes may contribute to mTLE. Specifi-
cally, for both CACNB4 and GRIA splicing changes, it would
Principal component analysis of ion channel splice variant expression  patterns for all experimental groups Figure 3
Principal component analysis of ion channel splice variant expression 
patterns for all experimental groups. (a) Colors separate groups based on 
statistical clustering (k-means clustering) of individuals with similar 
patterns of ion channel splicing. (b) Colors separate groups based on 
disease state and brain structure: control TC (blue), mTLE NC (red), AD 
TC (green), control CB (black), AD CB (yellow). The first principal 
component explains 43% of the variation in log expression ratios, while 
the second principal component accounts for 13% of the variation. 
Separation of clusters along principal components 1 and 2 is, to a large 
extent, governed by brain structure and disease state.
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be interesting to evaluate the relationship between SVRs and
seizure frequency/severity in animal models of epilepsy to
assess in vivo the consequences of the alterations.
Elucidating functional consequences of splice variants with unknown 
function
This work has, for the first time, established specific disease-
associated alternative splicing events across a broad category
of genes in two neurological diseases. With the generation of
these lists of disease-associated ion channel alternative
splicing events comes the task of deciphering the functional
consequences of these changes and how they may contribute
to the diseases. There are too many splicing changes associ-
ated with mTLE and AD to pursue comprehensive functional
evaluation to determine the biological impact of all proteins
expressed from alternatively spliced mRNA transcripts. A
strategy is clearly needed for selection of events for functional
evaluations.
One approach to identify the most clinically significant alter-
native splicing events is to evaluate the compiled lists for
mTLE (Table 1) and AD (Table 3) for splicing events that are
genetically controlled. Specifically, we propose evaluating
splice donor and acceptor regions for single nucleotide poly-
morphisms that may be responsible for alterations in SVRs
and to evaluate correlations between SVRs and genotypes.
We can then evaluate a large population of affected individu-
als for the presence of the polymorphism and certain clinical
phenotypes, such as measures of disease severity or
responsiveness to medications. In doing this, we would be
able to indirectly associate the splicing event with key clinical
outcomes. This approach would focus mechanistic investiga-
tion upon only the most disease-relevant changes. Further-
more, in knowing that a splicing change contributes to a
specific clinical endpoint, functional investigations can be
designed to evaluate specific and relevant mechanistic
hypotheses. This approach is exemplified by an SCN1A poly-
morphism located in the 5' consensus site region following
the neonatal form of exon 5 that has been found to be a genet-
ically controlled key alternative splicing event [43]. This pol-
ymorphism has been associated with altered doses of certain
antiepileptic drugs in two independent populations [6,44].
These findings have led to the hypothesis that the pharmacol-
ogy of these antiepileptic drugs may be altered in the presence
of decreased expression of the splice variant, and have guided
follow-up mechanistic work into how this might be occurring.
While many of the identified splicing changes reported herein
are not genetically controlled, it is not unreasonable to expect
that a proportion of them are. In cases where it is possible,
establishing genetic control of alternative splicing will serve
as a valuable platform for beginning to decipher their disease
significance.
Conclusion
Based on the few known examples of disease-associated splic-
ing events, the impact of elucidating the contribution of alter-
native transcript forms in human disease likely will be
substantial. EST and cDNA libraries provide valuable infor-
mation about potential alternative splice forms on a genome-
wide scale. It is not currently feasible to determine in a high
throughput manner which of these numerous events result in
a change in system biology. One possible direction is to con-
centrate on the functional significance of variant transcripts
associated with human disease. We undertook such a task by
evaluating brain tissue from mTLE and AD for disease-asso-
ciated alternative splice variants using a splice variant micro-
array, the first reported example of employing such an
approach in neurological disease. Collectively, our results
demonstrate that two common and important neurological
conditions are associated with widespread alterations in
splicing patterns of ion channel genes. While additional
experimentation is needed to establish the consequences of
these alternative splicing events in the diseases, these lists
provide a valuable foundation for elucidating which of these
events translate into clinically significant changes.
Materials and methods
Brain tissue samples
This study was approved by the Joint Research Ethics Com-
mittee of the Institute of Neurology and the National Hospital
for Neurology and Neurosurgery, and the Duke University
Institutional Review Board.
Freshly resected brain tissue from patients with mTLE was
used to identify key splicing changes associated with this type
of epilepsy. All these patients gave written informed consent
for use of the resected brain tissue for research. Temporal
neocortical tissue samples (n = 43) were obtained from mate-
rial resected from patients undergoing therapeutic surgery
for drug-resistant mTLE according to routine clinical proto-
cols at the National Hospital for Neurology and Neurosurgery
(London, UK). All tissue used for research was surplus to
diagnostic requirements. Patients were between the ages of
18 and 60 years and the group consisted of 15 males and 28
females. All had a diagnosis of hippocampal sclerosis con-
firmed histologically. The hippocampal tissue was excluded
from analysis due to potential confounding issues of exten-
sive, non-uniform, neuronal loss.
Nonepileptic/nondemented autopsy control and AD tempo-
ral cortical and cerebellar tissue was obtained through the
Kathleen Price Bryan Alzheimer's Disease Brain Bank at Duke
University. Subjects were enrolled prospectively and followed
until death as previously described [45]. Temporal cortex
samples were tested as this area is highly affected by AD,
while the cerebellum has minimal AD pathology, and was,
therefore, used as an internal control. Control subjects (n =
31) were between the ages of 56 and 90 years (mean 85.5http://genomebiology.com/2007/8/3/R32 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. R32.15
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2007, 8:R32
years) and consisted of 14 males and 17 females. AD patients
(n = 32) were between the ages of 79 and 90 years (mean 83.5
years) and consisted of 8 males and 24 females. All AD sub-
jects had AD pathology greater than Braak stage IV. All brain
tissue was collected postmortem with the time to collection
ranging from 1-30 h (mean 9.5 h) and 0.5-18.5 h (mean 8 h)
for control and AD, respectively. Autopsy control samples
were used as the control group for both epilepsy and AD. All
brain tissue was flash frozen in liquid nitrogen and stored at -
80°C until use.
Splice array
Ion channel splice arrays were purchased through ExonHit
Therapeutics (Gaithersburg, MD, USA). All known and pos-
tulated alternative splicing events involving ion channel
genes and their major associated interacting proteins were
included on the array (1,665 events in total). Each alterna-
tively spliced transcript defined a splicing event. The refer-
ence transcript was chosen for each gene by the company as
one of the most commonly accepted mRNA transcript forms.
The splice variant for a particular event is referred to as the
variant transcript. In all cases where a splicing event was
identified to be altered in epilepsy or AD, the GenBank acces-
sion numbers for both transcript forms and the affected exons
are provided in Tables 1 and 3 to define the specific exon
structure for the gene undergoing alternative splicing.
For each splicing event analyzed on the splice array, three to
six probes were used to quantify the event. The number of
probes selected for an event depended on the nature of the
splicing event and the ability to design an adequate probe for
the desired sequence (more detail about probe design is given
in Fehlbaum et al. [8]). Specifically, the complete probe sets
consisted of an A3 probe to monitor total transcript expres-
sion at the 3' end, an A5 probe for assessing total transcript
expression at the 5' end, a B probe designed to bind to a purely
exonic region specific to the reference or the variant (which
transcript depends on the event), a C and D probe to screen
for exon-exon junctions surrounding an exon unique to the
reference or the variant, and an E probe to assess a unique
exon-exon boundary in the transcript form not being
screened for by the B probe.
RNA extraction and splice array data collection
Brain tissue was ground in liquid nitrogen (mortar and pes-
tle). Tissue powder was separated into a 20-30 mg fraction for
RNA extraction and a 5-10 mg sample for protein extraction.
Total RNA was extracted from brain tissue using the RNeasy
Lipid Tissue Purification Kit (Qiagen, Valencia, CA, USA)
according to the manufacturer's instructions. The resulting
RNA was quantified spectrophotometrically. RNA was
extracted from all subjects comprising the experimental
groups (n = 43 for mTLE, n = 29 for control temporal cortex
(mTLE), n = 32 AD temporal cortex, and n = 31 control (AD)).
RNA from a subset of ten subjects from each group was
selected for splice array analysis.
Samples were selected for splice array analysis to provide for
the closest possible age and gender comparisons. To do this
effectively for each disease to control comparison, five of the
ten control samples overlapped for the AD and epilepsy eval-
uations. Coded aliquots of extracted total RNA from the
selected subjects were sent to ExonHit Therapeutics for Ion
Channel splice array analysis. Prior to dye-labeling and
hybridization, the RNA quality was assessed on an Agilent
Bioanalyzer (Palo Alto, CA, USA).
For the epilepsy splice variation scan, a set of ten samples per
group (controls and epilepsy samples) were submitted for the
comparison between mTLE neocortex and control temporal
cortex (control temporal cortex 1). A mTLE neocortex and a
control temporal cortex 1 sample were labeled with cy3 and
cy5 fluorescent dyes and hybridized to the splice array chip
simultaneously (two samples labeled with different dyes per
array). A total of ten splice arrays were used for the disease to
control comparison. The effects of potential dye bias were
minimized by labeling five of the ten samples comprising a
group with opposite dyes.
For the AD splice variation scan, splice array data were gen-
erated for a set of ten samples per group (AD temporal cortex,
control temporal cortex 2, cerebellum AD, and cerebellum
control 2). In all cases, matched temporal cortical and cere-
bellar tissue samples were obtained from each subject. An AD
and control sample were run together on a single chip in an
identical manner as described for the mTLE samples. The
same control versus AD comparison also was made for the
cerebellar samples. A total of 20 arrays were used for the anal-
ysis, with 10 arrays used for temporal cortex comparisons and
10 arrays used for cerebellar analyses.
All splice array data files are available through the Gene
Expression Omnibus (series accession numbers: mTLE neo-
cortex (GSE6773), control temporal cortex 1 (GSE6771), AD
temporal cortex (GSE6775), control temporal cortex 2
(GSE6774), cerebellum AD (GSE6777), and cerebellum con-
trol 2 (GSE6778)).
Splice array data analysis
In some cases, probes included on the splice array do not
hybridize to the RNA in the experimental sample either due to
a lack of the targeted sequence in the sample or because of a
failure of the probe to bind in a sample type. To address this
issue, probe hybridization fluorescence output values were
excluded for a particular splicing event if values were <200,
as this approaches the limit of detection of this technology. A
single probe hybridization value of <200 in a group resulted
in the complete elimination of that probe from the quantifica-
tion of that splice variant for that control versus disease com-
parison. Probe sets were eliminated across the entire disease-
control comparison only if they failed to hybridize in a partic-
ular brain structure regardless of disease state, and not if they
failed solely in the control or diseased brain tissue structure,R32.16 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. http://genomebiology.com/2007/8/3/R32
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as the latter could be caused by a disease-altered splicing
change.
Ratios of probe hybridization fluorescence outputs were used
to quantify the relative number of alternatively spliced tran-
scripts, and to control for any alterations in overall gene
expression. Selection of the best possible ratio for an event
was based on the following ratio priority: E/B > B/A3 = B/A5
> E/A3 = E/A5 > E/C = E/D. This priority system was largely
based on the rationale that the most sensitive measure of an
alternative splicing event will be to directly quantify variant to
reference ratios. This is particularly the case when the
changes in the reference and variant transcripts occur in con-
cert (that is, a reduction in reference occurs simultaneously
with an increase in variant). However, junction probes gener-
ally are shorter in length and, therefore, emit a less reliable
fluorescence output. Thus, for this study we accepted the less
reliable junction probe when it was normalized to a more reli-
able nonjunction probe (E/B), but deemed the dual junction
probe ratio (E/C or E/D) to be of lower priority. The A3 and
A5 probes are longer probes that often span several exons
and, therefore, provide reliable hybridization fluorescence
outputs. However, in a gene where there are several alterna-
tive splicing events, normalizing to one of the probes screen-
ing for total transcript expression (A3 or A5) may actually be
quantifying more than one splicing event. Therefore, the
strategy of normalizing to total transcript expression was
placed as lower priority to the more specific variant/reference
(E/B) normalization ratio. In addition to this priority system,
it also was necessary to select a ratio that was available in all
groups for most accurate comparison. For example, when
comparing AD to control, the E/B ratio would be selected only
if it were available in the AD and control temporal cortex and
cerebellum samples. If the E/B ratio was not available for any
of the groups (due to one of the probes being below the limit
of detection in a group), then the next highest priority ratio
was selected. The selected ratio was defined as the SVR for a
particular variant.
Using this selection procedure, SVRs were defined for all of
the splice variants for both the mTLE and AD comparisons.
For AD, following selection of a common SVR across all four
groups, an additional ratio was taken normalizing the tempo-
ral cortex ratio to the cerebellum ratio (TC/CB) for each indi-
vidual. A Student's t-test was then used to identify particular
splicing events with a statistically significant change in epi-
lepsy and AD using the following comparisons:
mTLE: SVRTC, control2 vs. SVRNC, mTLE   (equation 1)
Lists were made of the events that had a statistically signifi-
cant alteration (p < 0.05). Of these, several were selected for
quantitative real time PCR follow-up evaluations to test the
accuracy of the splice array findings. As negative controls, a
total of four events that were not found to be significantly
changed in mTLE or AD were also selected for follow-up
rtPCR confirmation. rtPCR follow-up was carried out in a
larger sample set, also including all of the original samples.
All splice array data analysis was performed in Microsoft
Excel. All data inputs and calculations were verified by two
individuals. Final compiled sheets were checked by manual
calculation of randomly selected splicing events.
Due to the differences in time of brain tissue collection in the
AD experiments, linear regression analyses were performed
comparing the proportion of alternative transcripts versus
the time of postmortem brain tissue collection in control and
AD brain tissue. For events identified in epilepsy, correlations
were assessed only in control tissue, as all the mTLE neocor-
tical tissue was freshly collected.
Real time PCR
To confirm splicing events identified in the splice array, and
to estimate the magnitude of the effect in a larger set of sam-
ples, rtPCR was employed. RNA from all subjects comprising
the groups (including the ten sent for splice array analysis)
was used in the rtPCR analyses. A total RNA sample from all
subjects was reverse transcribed into cDNA using a High
Capacity cDNA Synthesis Kit (Applied Biosystems, Foster
City, CA, USA) according to product instructions. Taqman®
assays and custom-designed primer/probe sets that were
used in rtPCR studies to confirm the presence of the splice
variants are given in Additional data file 1. All rtPCR assays
were purchased through Applied Biosystems and run per the
manufacturer's protocol using 10-20 ng of total RNA (con-
verted to cDNA) per reaction.
Standard curves were run for a range of total RNA (converted
to cDNA, 9 standards ranging from 0.01-100 ng). Number of
cycles to reach a threshold fluorescence reading (CT) was plot-
ted against log RNA amount and a line was fitted to the data
points using linear regression. The following equation was
used to quantify the number of transcripts present in an
experimental sample:
Where, CT, sample is the number of cycles to reach the fluores-
cence threshold for a given sample, and y0 and α are, respec-
tively, the intercept and slope of the line defining the
relationship of CT versus log(RNA amount) determined from the
standard curve [46]. Using this approach, differences in
amplification efficiency are accounted for, thereby permitting
relative quantification between the two transcript forms. Rel-
ative proportions of splice variants were quantified by divid-
ing the number of transcripts in the variant form to the
number of transcripts in the reference form. Occasionally, it
AD
SVR
SVR
vs
SVR
SVR
TC control
CB control
TC AD
CB AD
:.
,
,
,
,
1
1
   equatio on 2 ()
Number of transcripts
Cy TS a m p l e    equation  =
− ⎛
⎝
⎜ ⎜
⎞
⎠
⎟ ⎟ 10 3
0 ^
() ,
α ( ()http://genomebiology.com/2007/8/3/R32 Genome Biology 2007,     Volume 8, Issue 3, Article R32       Heinzen et al. R32.17
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2007, 8:R32
was necessary to normalize to total expression of the two
transcripts forms (by probing for transcript region common
to both) due to assay development restrictions.
Principal components analyses
Principal component analyses on covariances between log-
transformed SVRs within individuals were used to identify
the most significant sources of variability between brain tis-
sue samples collected from diseased and nondiseased
patients. K-means clustering was performed to group individ-
uals with similar alternative splicing profiles. Linear
regression models were fitted to the data points defining AD
and control samples along the most important principal com-
ponent axes to determine the contribution of disease state in
both disease-affected and unaffected brain structures. Princi-
pal component analyses were performed using JMP software
(version 5.1.2, Cary, NC, USA). Linear regression analyses
were performed using SPSS software (version 13, Chicago, IL,
USA).
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 contains Taqman®
assays and custom-designed primer/probe sequences that
were used in rtPCR studies to confirm the presence of the
splice variants. Additional data file 2 contains additional
methods, discussion and figures regarding the assessment of
cellular composition of the brain tissue samples used in these
studies.
Additional data file 1 Taqman® assays and custom-designed primer/probe sequences  used in rtPCR studies to confirm the presence of the splice variants Taqman® assays and custom-designed primer/probe sequences  used in rtPCR studies to confirm the presence of the splice variants. Click here for file Additional data file 2 Additional methods, discussion and figures regarding the assess- ment of cellular composition of the brain tissue samples used in  these studies Additional methods, discussion and figures regarding the assess- ment of cellular composition of the brain tissue samples used in  these studies. Click here for file
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